<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26526623</article-id><article-id pub-id-type="pmc">4630884</article-id><article-id pub-id-type="publisher-id">1871</article-id><article-id pub-id-type="doi">10.1186/s12885-015-1871-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fujimura</surname><given-names>Tetsuya</given-names></name><address><email>tfujimura-jua@umin.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Satoru</given-names></name><address><email>takahashi.satoru@nihon-u.ac.jp</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kume</surname><given-names>Haruki</given-names></name><address><email>kume@kuc.biglobe.ne.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Urano</surname><given-names>Tomohiko</given-names></name><address><email>turanotky@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Takayama</surname><given-names>Kenichi</given-names></name><address><email>knt56ta@hotmail.com</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Yuta</given-names></name><address><email>yyamada2029@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Motofumi</given-names></name><address><email>uromotofumi@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Fukuhara</surname><given-names>Hiroshi</given-names></name><address><email>hifukuha@bk9.so-net.ne.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Nakagawa</surname><given-names>Tohru</given-names></name><address><email>tohru-tky@umin.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Satoshi</given-names></name><address><email>sinoue07@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Homma</surname><given-names>Yukio</given-names></name><address><email>homma-uro@umin.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan </aff><aff id="Aff2"><label/>Department of Urology, Graduate School of Medicine, The Nihon University, Tokyo, Japan </aff><aff id="Aff3"><label/>Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan </aff><aff id="Aff4"><label/>Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>836</elocation-id><history><date date-type="received"><day>16</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Fujimura et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Backgrounds</title><p>Durability of androgen-deprivation therapy (ADT) for prostate cancer (PC) is limited. Additional selective estrogen receptor modulators (SERMs) may prolong the durability of ADT, because androgen and estrogen signaling drive PC progression.</p></sec><sec><title>Methods</title><p>Men with treatment-na&#x000ef;ve bone metastatic PC were randomly assigned in 1:1:1 fashion to receive ADT, toremifene 60&#x000a0;mg plus ADT (TOPADT), or raloxifene 60&#x000a0;mg plus ADT (RAPADT). The primary endpoint was the biochemical recurrence (BCR) rate, and secondary endpoints were changes of scores of the visual analogue scale (VAS) and the functional assessment of cancer therapy (FACT).</p></sec><sec><title>Results</title><p>A total of 15 men, 5 each, were allocated to one of the three treatment arms. The basal serum prostate-specific antigen (PSA) level was 198&#x000a0;ng/mL (median, range; 30&#x02013;8428). Bone metastases were graded as 1 (<italic>n</italic>&#x02009;=&#x02009;11), 2 (<italic>n</italic>&#x02009;=&#x02009;3), and 3 (<italic>n</italic>&#x02009;=&#x02009;1) by the extent of disease. During the median follow-up period of 1370&#x000a0;days (range; 431&#x02013;1983), BCR occurred in 3, 0 and 2 men in ADT, TOPADT and RAPADT group, respectively. The 5-year BCR-free rate was 30, 100 and 53&#x000a0;%, in ADT, TOPADT and RAPADT group, respectively (<italic>p</italic>&#x02009;=&#x02009;0.04, ADT v.s. TOPADT, <italic>p</italic>&#x02009;=&#x02009;0.48, ADT v.s. RAPADT and <italic>p</italic>&#x02009;=&#x02009;0.12, TOPADT v.s. RAPADT). Scores of VAS improved in all groups and remained stable throughout the study. This analysis is limited as a preliminary result in a single center.</p></sec><sec><title>Conclusions</title><p>Toremifene with conventional ADT significantly improved the BCR rate in treatment-na&#x000ef;ve bone metastatic PC. Further clinical trials are warranted to confirm the promising clinical efficacy of this combination therapy.</p></sec><sec><title>Trial registration</title><p>The protocol was registered at the University Hospital Medical Information Network (<ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=confirm&#x00026;action=brows&#x00026;recptno=R000007596&#x00026;key=1008qrVyfJumTw7i9SC41aEp">UMIN ID;0,000,064,000</ext-link>) in Sep 25, 2011.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12885-015-1871-z) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Toremifene</kwd><kwd>Raloxifene</kwd><kwd>Androgen deprivation therapy</kwd><kwd>Biochemical recurrence</kwd><kwd>Prostate cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Based on the pioneering work by Huggins [<xref ref-type="bibr" rid="CR1">1</xref>], androgen deprivation therapy (ADT) has been the primary treatment for advanced prostate cancer (PC). Unfortunately, most advanced cases of PC eventually become castration-resistant (CRPC), despite the continued use of ADT [<xref ref-type="bibr" rid="CR2">2</xref>]. Novel therapies such as docetaxel, enzaltamide, abiraterone, cabazitaxel and sipuleucel-T [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>] have been developed to treat CRPC. However, the development of agents that inhibit progression to CRPC may represent alternative therapeutic options for PC.</p><p>The results of recent studies have revealed growth regulation of PC via steroid nuclear receptors, which included not only the androgen receptor (AR) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] but also members of the estrogen receptor (ER) family [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. ER&#x003b1; and ER&#x003b2;cx (ER&#x003b2;2) in particular have been implicated in PC progression and PC-related mortality, whereas ER&#x003b2; inhibits tumor growth [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In this regard, selective estrogen receptor modulators (SERMs) are expected to change the clinical course of PC. For example, toremifene, an ER&#x003b1; antagonist in the prostate [<xref ref-type="bibr" rid="CR10">10</xref>], decreased the incidence of PC in men with high-grade prostatic intraepithelial neoplasia (HGPIN) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Furthermoere, raloxifene inhibited androgen-independent PC growth in 5 (28&#x000a0;%) of 13 patients [<xref ref-type="bibr" rid="CR13">13</xref>]. However, SERMs have not been fully investigated for use in those with treatment-na&#x000ef;ve PC. We hypothesized that additional SERMs may prolong the durability of ADT, because androgen and estrogen signaling drive PC progression. In the present study, we conducted a prospective randomized clinical phase IIA trial to investigate the effects of SERMs (toremifene and raloxifene) when added to ADT in treatment-na&#x000ef;ve bone metastatic PC.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><p>The inclusion criteria were men aged &#x02265;20&#x000a0;years if they had histological confirmed adenocarcinoma of the prostate and radiologically proven bone metastasis with performance status 0, and adequate hepatic, hematological and renal function. Patients who had previous ADT or chemotherapy for PC, deep vein thrombosis, pulmonary embolism or antiphospholipid antibody syndrome were excluded. Bisphosphonate, warfarin, phenobarbital, rifampicin, phenitoin, ampicillin or cholestyramine was not allowed during the study.</p><p>Extent of diseases (EOD) of bone metastasis was graded by bone scintigraphy using technetium-99&#x000a0;m-methylene diphosphonate as follows: 0, normal or abnormal due to benign bone disease; 1, number of bony metastases &#x0003c;6, each of which was &#x0003c;50&#x000a0;% of the size of a vertebral body (one lesion approximately the size of a vertebral body would be counted as two lesions); 2, number of bone metastases between 6 and 20, size of lesions as previously described; 3, number of metastases &#x02265;20 but less than a &#x0201c;super scan&#x0201d;, and 4, &#x0201c;super scan&#x0201d; or its equivalent, i.e., more than 75&#x000a0;% of the ribs, vertebrae and pelvic bones [<xref ref-type="bibr" rid="CR14">14</xref>]. The Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score (range; 0&#x02013;12) was calculated on the basis of GS, PSA levels and clinical stage [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>The protocol was approved by the ethical committee (Internal Review Board) at the University of Tokyo Hospital in August 2008 (approval number; P2008054) entitled preliminary study of selective estrogen modulators (SERMs) combined with maximum androgen blockade for metastatic prostate cancer (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). And the study was also registered at the University Hospital Medical Information Network (UMIN ID; 0000064000). All patients provided written informed consent. An analysis was performed and reported to the Internal Review Board in the University of Tokyo Hospital every year.</p></sec><sec id="Sec4"><title>Study design</title><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the consolidated standards of reporting trials (CONSORT) flow diagram of recruited patients and follow-up. Eligible patients were randomly allocated in a 1:1:1 fashion to receive ADT alone, toremifene plus ADT (TOPADT) or raloxifene plus ADT (RAPADT). ADT consisted of castration [bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonists] combined with 80&#x000a0;mg of bicalutamide. The LHRH agonist was administered throughout, whereas bicalutamide was changed to flutamide on biochemical recurrence after denying anti-androgen withdrawal syndrome. Toremifene (Orion Corporation, Finland) and raloxifene (Eli Lilly Japan K.K.) were given at a dose of 60&#x000a0;mg orally every day combined with aspirin 100&#x000a0;mg daily for prophylactic anti-coagulation.<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT flow diagram of recruited patients and follow-up. Men diagnosed with PC by trans-rectal prostate needle biopsy underwent a bone scan. If patients had bone metastasis and agreed to participate in the trial, they were assigned to receive ADT alone, TOPADT or RAPADT in a 1:1:1 ratio (<italic>n</italic>&#x02009;=&#x02009;15)</p></caption><graphic xlink:href="12885_2015_1871_Fig1_HTML" id="MO1"/></fig></p><p>After PC became hormone-refractory, administration of flutamide was switched to systemic chemotherapy which was performed every 3&#x02013;4&#x000a0;weeks. If PC became both hormone refractory and chemotherapy-refractory, patients received best supportive care.</p></sec><sec id="Sec5"><title>Study end points</title><p>Patients were monitored every month during the first year, and every 3&#x000a0;months thereafter. The primary endpoint was the BCR, which was defined as consecutive increase in serum PSA levels to above the patient&#x02019;s PSA nadir [<xref ref-type="bibr" rid="CR16">16</xref>]. Secondary endpoints included pain on a visual analogue scale (VAS) and functional assessment of cancer therapy (FACT) in every 3&#x000a0;months [<xref ref-type="bibr" rid="CR17">17</xref>].</p><sec id="Sec6"><title>Immunohistochemical analysis</title><p>The immunohistochemical analyses for AR, ER&#x003b1; and ER&#x003b2; were performed using the streptavidin-biotin amplification method and an EnVision&#x02009;+&#x02009;visualization kit (Dako, Carpinteria, CA, USA) as previously described [<xref ref-type="bibr" rid="CR9">9</xref>]. The primary antibody against AR (1:40 dilution), ER&#x003b1; (1:40 dilution) and ER&#x003b2; (1:200 dilution) was applied and incubated at room temperature for 1&#x000a0;h. The sections were then rinsed in phosphate-bufferes saline and incubated at room temperature with EnVision&#x02009;+&#x02009;for 1&#x000a0;h. The antigen-antibody complex was visualized with 3, 3&#x02032;-diaminobenzidine (DAB) solution [1&#x000a0;mM DAB, 50&#x000a0;mM Tris&#x02013;HCl buffer (pH&#x000a0;7.69, and 0.006&#x000a0;% H<sub>2</sub>O<sub>2</sub>]. The monoclonal antibodies for AR (AR441) and ER&#x003b1; (NCL-ER-6&#x000a0;F11) were purchased from Dako (Dako, Carpinteria, CA, USA) and Novo-castra Laboratories (Newcastle upon Tyne, UK), respectively. A polyclonal antibody specific for ER&#x003b2; was raised in rabbits against peptides synthesized to correspond to the C-terminal region of ER&#x003b2; (CSPAEDSKSKEGSQNPQSQ) [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec7"><title>Immunohistochemical assessment</title><p>The labeling index (LI) was determined by counting the percentage of cells with positive immunoreactivity per 1000 cells [<xref ref-type="bibr" rid="CR18">18</xref>]. Two trained pathologists (TF and YY) independently evaluated the tissue sections, and the average LI was used. We defined positive immunoreactivity as showing moderate or strong immunoreactivity.</p></sec></sec><sec id="Sec8"><title>Statistical analyses</title><p>Correlations between age, pretreatment serum PSA levels, J-CAPRA score [<xref ref-type="bibr" rid="CR15">15</xref>], and LI were evaluated using the Wilcoxon rank sum test. Associations between the group and clinical parameters including Gleason score (GS) and clinical stage were assessed using chi-square tests. BCR-free survival curves were plotted using the Kaplan-Meier method and verified using the log-rank test and univariate Cox proportional hazards regression models. JMP 11.0.0 software (SAS Institute, Cary, NC, USA) was used for all statistical analyses, and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered to indicate statistical significance.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Patient characteristics</title><p>From August 14, 2008 to December 27, 2012, 15 patients were enrolled and randomly allocated to either of the three treatment groups as shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The median age was 74&#x000a0;years (range, 63&#x02013;85). Pretreatment serum PSA levels were 30&#x02013;8428&#x000a0;ng/mL (median, 198&#x000a0;ng/mL). The biopsy samples were evaluated by two pathologists as GS 7 (<italic>n</italic>&#x02009;=&#x02009;3), 8 (<italic>n</italic>&#x02009;=&#x02009;5), 9 (<italic>n</italic>&#x02009;=&#x02009;5), or 10 (<italic>n</italic>&#x02009;=&#x02009;2). The median J-CAPRA score was 9 (range, 6&#x02013;11). There was no statistically significant difference in age, serum PSA level, stage, GS, EOD, J-CAPRA score or LI against the anti-AR, &#x02212;ER&#x003b1;, and-ER&#x003b2; antibodies among the three groups [ADT v.s. TOPADT and ADT v.s. RAPADT; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics (<italic>n</italic>&#x02009;=&#x02009;15)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>ADT (<italic>n</italic>&#x02009;=&#x02009;5)</th><th>TOPADT (<italic>n</italic>&#x02009;=&#x02009;5)</th><th>
<italic>P</italic> value (vs. ADT)</th><th>RAPADT (<italic>n</italic>&#x02009;=&#x02009;5)</th><th>
<italic>P</italic> value (vs. ADT)</th></tr></thead><tbody><tr><td>Age (median, range)</td><td/><td>76 (74&#x02013;85)</td><td>73 (63&#x02013;81)</td><td>0.59</td><td>72 (67&#x02013;75)</td><td>0.29</td></tr><tr><td>PSA (ng/mL) (median, range)</td><td/><td>223 (30.6&#x02013;8428)</td><td>264 (30&#x02013;818)</td><td>1</td><td>126 (30.8&#x02013;3600)</td><td>0.83</td></tr><tr><td rowspan="4">Gleason score</td><td>7</td><td>1</td><td>0</td><td rowspan="4">0.72</td><td>2</td><td rowspan="4">0.57</td></tr><tr><td>8</td><td>2</td><td>2</td><td>1</td></tr><tr><td>9</td><td>1</td><td>2</td><td>2</td></tr><tr><td>10</td><td>1</td><td>1</td><td>0</td></tr><tr><td rowspan="4">Clinical T stage</td><td>2c</td><td>2</td><td>4</td><td rowspan="4">0.19</td><td>2</td><td rowspan="4">0.55</td></tr><tr><td>3a</td><td>3</td><td>1</td><td>2</td></tr><tr><td>3b</td><td>0</td><td>0</td><td>0</td></tr><tr><td>4</td><td>0</td><td>0</td><td>1</td></tr><tr><td rowspan="2">Clinical N stage</td><td>0</td><td>2</td><td>4</td><td rowspan="2">0.19</td><td>1</td><td>1</td></tr><tr><td>1</td><td>3</td><td>1</td><td>4</td><td/></tr><tr><td rowspan="2">Clinical M stage</td><td>1b</td><td>5</td><td>4</td><td>1</td><td>5</td><td>1</td></tr><tr><td>1c</td><td>0</td><td>1: lung</td><td/><td>0</td><td/></tr><tr><td rowspan="3">Extent of disease</td><td>1</td><td>4</td><td>3</td><td rowspan="3">0.49</td><td>4</td><td rowspan="3">1</td></tr><tr><td>2</td><td>0</td><td>2</td><td>1</td></tr><tr><td>3</td><td>1</td><td>0</td><td>0</td></tr><tr><td>J-CAPRA score (median, range)</td><td/><td>9 (8&#x02013;10)</td><td>8 (7&#x02013;9)</td><td>0.37</td><td>9 (6&#x02013;11)</td><td>0.92</td></tr><tr><td colspan="7">Labeling index (median, range)</td></tr><tr><td>AR</td><td/><td>78.5 (54.8&#x02013;100)</td><td>87.1 (30&#x02013;100)</td><td>1</td><td>100 (37.5&#x02013;100)</td><td>0.68</td></tr><tr><td>ER&#x003b1;</td><td/><td>27.9 (0&#x02013;46.5)</td><td>19.7 (0&#x02013;37.4)</td><td>0.34</td><td>20.6 (13.4&#x02013;35.4)</td><td>0.54</td></tr><tr><td>ER&#x003b2;</td><td/><td>20.3 (2.4&#x02013;44.9)</td><td>11.9 (7.4&#x02013;91.4)</td><td>0.75</td><td>15.2 (7&#x02013;26.4)</td><td>0.9</td></tr></tbody></table><table-wrap-foot><p>
<italic>ADT</italic> androgen deprivation therapy including surgical or medical castration plus bicalutamide, <italic>TOPADT</italic> toremifene plus ADT, <italic>RAPADT</italic> raloxifene plus ADT, <italic>J-CAPRA score</italic> Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score (ranging from 0 to 12) was calculated on the basis of PSA, Gleason score and clinical stage [<xref ref-type="bibr" rid="CR15">15</xref>]. Labeling index was determined by counting the percentage of cells with positive immunoreactivity in 1000 cells [<xref ref-type="bibr" rid="CR18">18</xref>], <italic>AR</italic> androgen receptor, <italic>ER</italic> estrogen receptor</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Immunohistochemical staining for AR (<bold>a</bold>), ER&#x003b1; (<bold>b</bold>) and ER&#x003b2; (<bold>c</bold>) in the tissue sections from the same area of a patient with PC. Strong (<bold>a</bold>) or moderate (<bold>b</bold> and <bold>c</bold>) staining was identified in the nuclei of cancer cells. The LI of AR (<bold>a</bold>), ER&#x003b1; (<bold>b</bold>) and ER&#x003b2; (<bold>c</bold>) in cancer cells was 100, 35.4 and 26.4, respectively. Scale bar =100&#x000a0;&#x003bc;m</p></caption><graphic xlink:href="12885_2015_1871_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec11"><title>Primary endpoint</title><p>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows the PSA response and outcome after ADT with or without SERMs. One patient discontinued toremifene becauseof a headache during the median follow-up period of 1370&#x000a0;days (range, 431&#x02013;1983). Five (33&#x000a0;%) (2, 2, 1 in the three groups, respectively) patients achieved a PSA-nadir &#x02264;0.01. At the end of the follow-up period, 5 (33&#x000a0;%) patients (3 in the ADT group and 2 in the RAPADT group) experienced BCR and were switched from bicaltamide to flutamide. One patient in the ADT group became hormone-refractory rapidly and died of PC on day 431 without chemotherapy. One patient in the TOPADT group died of gastric cancer without showing BCR on day 1371. The BCR-free survival rate was significantly higher in men treated with TOPADT than in those received ADT only (<italic>p</italic>&#x02009;=&#x02009;0.04, ADT vs. TOPADT; <italic>p</italic>&#x02009;=&#x02009;0.48, ADT vs. RAPADT;, and <italic>p</italic>&#x02009;=&#x02009;0.12, TOPADT vs. RAPADT; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>PSA response and outcome after ADT with or without selective estrogen receptor modulators (<italic>n</italic>&#x02009;=&#x02009;15)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th>ADT (<italic>n</italic>&#x02009;=&#x02009;5)</th><th>TOPADT (<italic>n</italic>&#x02009;=&#x02009;5)</th><th>RAPADT (<italic>n</italic>&#x02009;=&#x02009;5)</th></tr></thead><tbody><tr><td colspan="2">Follow-up period (median, range)</td><td>1169 (431&#x02015;1631)</td><td>1653 (730&#x02015;1983)</td><td>1570 (750&#x02015;1883)</td></tr><tr><td rowspan="3">PSA nadir (ng/mL)</td><td>&#x02265;1</td><td>1</td><td>0</td><td>1</td></tr><tr><td>0.01&#x02013;1.0</td><td>2</td><td>3</td><td>3</td></tr><tr><td>&#x02264;0.01</td><td>2</td><td>2</td><td>1</td></tr><tr><td rowspan="2">Biochemical recurrence</td><td>No</td><td>2</td><td>5</td><td>3</td></tr><tr><td>Yes</td><td>3</td><td>0</td><td>2</td></tr><tr><td rowspan="3">Outcome</td><td>Alive with disease</td><td>4</td><td>4</td><td>5</td></tr><tr><td>Died of PC</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Died of other disease</td><td>0</td><td>1: Died of gastric cancer</td><td>0</td></tr><tr><td>Adverse event</td><td/><td>Hot flush: 2</td><td>Hot flush: 3, Headache: 1</td><td>Hot flush: 3</td></tr></tbody></table><table-wrap-foot><p>
<italic>ADT</italic> androgen deprivation therapy including surgical or medical castration plus bicalutamide, <italic>TOPADT</italic> toremifene plus ADT, <italic>RAPADT</italic> raloxifene plus ADT, <italic>PC</italic> prostate cancer</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>PSA relapse-free survival rates in men with TOPADT, RAPADT and ADT alone (<italic>n</italic>&#x02009;=&#x02009;15). The PSA relapse-free survival rate in men treated with TOPADT was significantly greater than in men treated with ADT alone (<italic>p</italic>&#x02009;=&#x02009;0.04)</p></caption><graphic xlink:href="12885_2015_1871_Fig3_HTML" id="MO3"/></fig></p><p>Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows the results obtained from univariate Cox proportional hazards regression models for BCR associated with treatment and the clinicopathological characteristics of the patients, including age, serum PSA levels, J-CAPRA score and LI of AR, ER&#x003b1; and ER&#x003b2;. TOPADT was only found to be significant in the univariate analysis (<italic>p</italic>&#x02009;=&#x02009;0.023; hazard ratio, 1.1 e<sup>&#x02212;9</sup>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Univariate Cox proportional hazard regression models of biochemical recurrence free survival (<italic>n</italic>&#x02009;=&#x02009;15)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Univariate</th></tr><tr><th>Variable</th><th>Hazard ratio</th><th>95&#x000a0;% index</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td>Age (&#x02265;74 vs. &#x0003c;74)</td><td char="." align="char">3.9</td><td char="&#x02013;" align="char">0.57&#x02013;75</td><td char="." align="char">0.18</td></tr><tr><td>Serum PSA (ng/mL) (&#x02265;198 vs. &#x0003c;198)</td><td char="." align="char">1.9</td><td char="&#x02013;" align="char">0.33&#x02013;15</td><td char="." align="char">0.45</td></tr><tr><td>J-CAPRA (&#x02265;9 vs. &#x02264;8)</td><td char="." align="char">1.7</td><td char="&#x02013;" align="char">0.27&#x02013;12</td><td char="." align="char">0.57</td></tr><tr><td>AR LI (&#x02265;93.5 vs. &#x0003c;93.5)</td><td char="." align="char">1.2</td><td char="&#x02013;" align="char">0.19&#x02013;8.7</td><td char="." align="char">0.87</td></tr><tr><td>ER&#x003b1; LI (&#x02265;23.2 vs. &#x0003c;23.2)</td><td char="." align="char">0.40</td><td char="&#x02013;" align="char">0.05&#x02013;2.5</td><td char="." align="char">0.32</td></tr><tr><td>ER&#x003b2; LI (&#x02265;16.1 vs. &#x0003c;16.1)</td><td char="." align="char">0.73</td><td char="&#x02013;" align="char">0.09&#x02013;4.4</td><td char="." align="char">0.73</td></tr><tr><td>TOPADT vs. MAB</td><td char="." align="char">1.1 e<sup>&#x02212;9</sup>
</td><td char="&#x02013;" align="char">0.64&#x02013;0.64</td><td char="." align="char">0.023</td></tr><tr><td>RAPADT vs. MAB</td><td char="." align="char">0.5</td><td char="&#x02013;" align="char">0.069&#x02013;3.2</td><td char="." align="char">0.48</td></tr></tbody></table></table-wrap></p><p>Hot flush was observed in all groups; ADT (<italic>n</italic>&#x02009;=&#x02009;2), TOPADT (<italic>n</italic>&#x02009;=&#x02009;3), and RAPADT (<italic>n</italic>&#x02009;=&#x02009;3); although, all patients continued on therapy.</p></sec><sec id="Sec12"><title>Secondary endpoint</title><p>The VAS scores were significantly decreased after treatment (<italic>p</italic>&#x02009;=&#x02009;0.04, pre-treatment vs. 3&#x000a0;months thereafter), and showed no statistical differences among the three groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Scores of physical well-being, social well-being, emotional well-being, functional well-being, as well as PC subscale scores of FACT questionnaire, were stable during the follow-up period and not statistically different among the three groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>&#x02013;<xref rid="Fig4" ref-type="fig">f</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>The change in VAS scores following treatment for PC (<bold>a</bold>). The VAS scores were significantly decreased after the treatment (<italic>p</italic>&#x02009;=&#x02009;0.04, pre treatment vs. 3, 6, 9 and 12&#x000a0;months of treatment). Statistically significant differences were not detected among the three groups. The FACT of before treatment and after 3, 6, 9 and 12&#x000a0;months of treatment. Physical well-being (PWB; <bold>b</bold>), social well-being (SWB; <bold>c</bold>), emotional well-being (EWB; <bold>d</bold>), functional well-being (FWB; <bold>e</bold>) and prostate cancer (PC) scale scores (<bold>f</bold>) were stable during the follow-up period. Statistically significant differences were not detected among the three groups in PWB (<italic>p</italic>&#x02009;=&#x02009;0.5, pre treatment v.s. 3, 6, 9 and 12&#x000a0;months of treatment), SWB (<italic>p</italic>&#x02009;=&#x02009;0.5, pretreatment vs. 3, 6, 9 and 12&#x000a0;months of treatment), EWB (<italic>p</italic>&#x02009;=&#x02009;0.75, pre treatment v.s. 3, 6, 9 and 12&#x000a0;months of treatment), FWB (<italic>p</italic>&#x02009;=&#x02009;0. 5, pretreatment vs. 3, 6, 9 and 12&#x000a0;months of treatment), and PC sub scale (<italic>p</italic>&#x02009;=&#x02009;0.25, pretreatment v.s. 3, 6, 9 and 12&#x000a0;months of treatment)</p></caption><graphic xlink:href="12885_2015_1871_Fig4_HTML" id="MO4"/></fig></p></sec></sec><sec id="Sec13"><title>Discussion</title><p>The most common initial therapy for metastatic PC is ADT; however, the durability of ADT is limited and affected by various factors including pretreatment PSA level, GS, tumor stage and PSA nadir [<xref ref-type="bibr" rid="CR19">19</xref>]. The durability of ADT is also influenced by the ER status of the tumor [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p>In fact, estrogens were initially used as one of the earliest forms of treatment agents; however, they were associated with thromboembolic and cardiovascular side effects [<xref ref-type="bibr" rid="CR21">21</xref>]. SERMs are synthetic estrogen ligands that can exhibit either estrogenic or anti-estrogenic effects depending on tissue types [<xref ref-type="bibr" rid="CR22">22</xref>]. Toremifene significantly reduced the incidence of PC in a transgenic adenocarcinoma mouse prostate model [<xref ref-type="bibr" rid="CR23">23</xref>], as well as in men with HGPIN [<xref ref-type="bibr" rid="CR11">11</xref>]. In addition, toremifene increased the bone mineral density of the hip and spine [<xref ref-type="bibr" rid="CR24">24</xref>] and improved lipid profiles in men receiving ADT for PC [<xref ref-type="bibr" rid="CR25">25</xref>]. Raloxifene, which acts as an ER agonist in the bone tissue [<xref ref-type="bibr" rid="CR26">26</xref>], has been developed for the treatment of osteoporosis in women [<xref ref-type="bibr" rid="CR27">27</xref>] and showed some tumor-inhibitory effects in CRPC in a pilot study [<xref ref-type="bibr" rid="CR13">13</xref>]. To date, the anti-cancer effects of these SERMs have not yet been fully investigated in treatment-na&#x000ef;ve PC patients. We hypothesized that concurrent use of SERMs would prolong the duration of efficacy of ADT in men with bone metastatic PC.</p><p>Currently, we have demonstrated that TOPADT significantly improved the biochemical recurrence rate in men with bone metastatic PC compared with men treated with ADT alone. The results of a recent study showed that the 5-year BCR-free rate was 30&#x000a0;% in men who received ADT plus docetaxel with median serum PSA levels of 26.7 (range, 5.0&#x02013;106) [<xref ref-type="bibr" rid="CR5">5</xref>]. In our study, similar rates were noted for men treated with ADT alone (30&#x000a0;%). Surprisingly, the 5-year BCR-free rate in the TOPADT group was 100&#x000a0;%.</p><p>Theoretically, the tumor inhibitory effects of toremifene would be mediated via the suppression of ER&#x003b1;-related signals [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. ER&#x003b1; expression in PC cells was confirmed by immunohistochemistry and quantitative reverse transcription polymerase chain reaction analyses [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The mRNA expression of ER&#x003b1; was much lower than AR in PC cells (1:100 ratio); however, ER&#x003b1; expression in cancer-associated stromal cells was significantly related to cancer-specific survival in men with bone metastatic PC [<xref ref-type="bibr" rid="CR18">18</xref>]. ER&#x003b1; expression was negatively correlated with survival after radical prostatectomy in locally advanced PC [<xref ref-type="bibr" rid="CR29">29</xref>]. Additionally, ER&#x003b1; promoted proliferation by regulating <italic>MYC</italic> expression and glucose sensitivity in phosphatase and tensin homolog (PTEN)-deficient mouse PC cells [<xref ref-type="bibr" rid="CR8">8</xref>]. Conversely, depletion of <italic>ER&#x003b1;</italic> inhibited growth in PTEN-deficient mice via a reduction in <italic>MYC</italic> protein and alteration of glucose sensitivity [<xref ref-type="bibr" rid="CR8">8</xref>]. The results of present study demonstrated that toremifene significantly improved the durability of ADT, suggesting blockade of ER&#x003b1; signaling as a potential target for advanced PC.</p><p>ER&#x003b2; signaling has been associated with a tumor-inhibitory effect in PC through both the classical (ER&#x003b2; and estrogen-response element complex) and non-classical pathways (ER&#x003b2;, Kr&#x000fc;ppel-like zinc finger transcription factor 5, and adenosine 3&#x02032;,5&#x02032;-monophosphate response element-binding protein-binding protein complex) [<xref ref-type="bibr" rid="CR30">30</xref>]. ER&#x003b2; modulators are expected to inhibit PC growth. Raloxifene exhibits diverse activities via ER depending on whether ER&#x003b1; or ER&#x003b2; is expressed in the target organ [<xref ref-type="bibr" rid="CR26">26</xref>]. The results of the present study did not prove a distinct tumor-inhibitory effect mediated by RAPADT as compared to ADT alone. The difference in the reason tumor inhibitory effect between TOPADT and RAPADT may have been attributed to the potency of the drugs and the pattern of ER expression in PC cells. The tumor-inhibitory effect of fulvestrant, another ER&#x003b2; modulator, was limited because the median time to progression was only 4.3&#x000a0;months in men with CRPC treated with fulvestrant [<xref ref-type="bibr" rid="CR31">31</xref>]. Further investigations of additional ER&#x003b2; modulators are warranted with respect to their potential role in the inhibition of human PC.</p><p>The known adverse events associated with the use of SERMs include hot flushes, sweating, nausea, dizziness, edema, vomiting and thrombosis [<xref ref-type="bibr" rid="CR27">27</xref>]. In the present study, two men in the ADT group, two men in the TOPADT group, and three men in the RAPADT group complained of mild hot flushes; however, no medical intervention was deemed necessary. Only one man in the TOPADT group discontinued toremifene administration because of a headache. No events of liver dysfunction or thrombosis were observed.</p><p>The present study was not without limitations. The sample size was small, and the cohort was limited to a single institution in an all Asian population. A multicenter external validation study would be necessary to further elucidate the additional effect of toremifene on ADT that we found in patients with advanced PC.</p></sec><sec id="Sec14"><title>Conclusions</title><p>Results from the present study we demonstrated the good clinical efficacy and tolerability of TOPADT in patients with treatment-na&#x000ef;ve bone metastatic PC. Additional clinical trials with larger cohorts are warranted to confirm our promising phase IIA results.</p></sec></body><back><app-group><app id="App1"><sec id="Sec15"><title>Additional file</title><p><media position="anchor" xlink:href="12885_2015_1871_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>CONSORT 2010 checklist of information to include when reporting a cluster randomised trial. (DOCX 30&#x000a0;kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ADT</term><def><p>androgen-deprivation therapy</p></def></def-item><def-item><term>AR</term><def><p>androgen receptor</p></def></def-item><def-item><term>BCR</term><def><p>biochemical recurrence</p></def></def-item><def-item><term>CONSORT</term><def><p>consolidated standards of reporting trials</p></def></def-item><def-item><term>EOD</term><def><p>extent of disease</p></def></def-item><def-item><term>ER</term><def><p>estrogen receptor</p></def></def-item><def-item><term>FACT</term><def><p>functional assessment of cancer therapy</p></def></def-item><def-item><term>J-CAPRA</term><def><p>Japan Cancer of the Prostate Risk Assessment</p></def></def-item><def-item><term>LI</term><def><p>Labeling index</p></def></def-item><def-item><term>PC</term><def><p>prostate cancer</p></def></def-item><def-item><term>PSA</term><def><p>prostate-specific antigen</p></def></def-item><def-item><term>PTEN</term><def><p>phosphatase and tensin homolog</p></def></def-item><def-item><term>RAPADT</term><def><p>raloxifene plus ADT</p></def></def-item><def-item><term>SERM</term><def><p>selective estrogen receptor modulator</p></def></def-item><def-item><term>TOPADT</term><def><p>toremifene plus ADT</p></def></def-item><def-item><term>VAS</term><def><p>visual analogue scale</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare no conflict of interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>TF conceived of the study and wrote the draft. ST, SI and YH revised the draft. HK, YY, MS, HF and TN contributed to data collection and analysis. TU and KT contributed to data interpretation and analysis. All authors approved the final version.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by Grants from Yamaguchi Endocrine Research Foundation and by Grants from University of Tokyo Hospital. The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation or writing the draft. Raw data was the property of the University of Tokyo. All authors had final responsibility for the decision to submit for publication.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huggins</surname><given-names>C</given-names></name><name><surname>Hodges</surname><given-names>CV</given-names></name></person-group><article-title>Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate</article-title><source>Cancer Res</source><year>1941</year><volume>1</volume><fpage>293</fpage><lpage>7</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cookson</surname><given-names>MS</given-names></name><name><surname>Lowrance</surname><given-names>WT</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name><name><surname>Kibel</surname><given-names>AS</given-names></name></person-group><article-title>American Urological Association. Castration-resistant prostate cancer: AUA guideline amendment</article-title><source>J Urol</source><year>2015</year><volume>193</volume><fpage>491</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2014.10.104</pub-id><pub-id pub-id-type="pmid">25444753</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannock</surname><given-names>IF</given-names></name><name><surname>de Witt</surname><given-names>R</given-names></name><name><surname>Berry</surname><given-names>WR</given-names></name><name><surname>Horti</surname><given-names>J</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Chi</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</article-title><source>N Engl J Med.</source><year>2004</year><volume>351</volume><fpage>1502</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040720</pub-id><pub-id pub-id-type="pmid">15470213</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Hussain</surname><given-names>MH</given-names></name><name><surname>Lara</surname><given-names>PN</given-names><suffix>Jr</suffix></name><name><surname>Jones</surname><given-names>JA</given-names></name><name><surname>Taplin</surname><given-names>ME</given-names></name><etal/></person-group><article-title>compared with mitoxantrone and prednisone for advanced refractory prostate cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1513</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041318</pub-id><pub-id pub-id-type="pmid">15470214</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravis</surname><given-names>G</given-names></name><name><surname>Fizazi</surname><given-names>K</given-names></name><name><surname>Joly</surname><given-names>F</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Priou</surname><given-names>F</given-names></name><name><surname>Esterni</surname><given-names>B</given-names></name><etal/></person-group><article-title>Androgen-deprivation therapy alone or with or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU15): a randomized, open-label, phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70560-0</pub-id><pub-id pub-id-type="pmid">23306100</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tammela</surname><given-names>T</given-names></name></person-group><article-title>Endocrine treatment of prostate cancer</article-title><source>J Steroid Biochem Mol Biol</source><year>2004</year><volume>92</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2004.10.005</pub-id><pub-id pub-id-type="pmid">15663992</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culig</surname><given-names>Z</given-names></name><name><surname>Steiner</surname><given-names>H</given-names></name><name><surname>Bartsch</surname><given-names>G</given-names></name><name><surname>Hobisch</surname><given-names>A</given-names></name></person-group><article-title>Mechanism of endocrine therapy-responsive and &#x02013;unresponsive prostate tumors</article-title><source>Endocr Relat Cancer.</source><year>2005</year><volume>12</volume><fpage>229</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1677/erc.1.00775a</pub-id><pub-id pub-id-type="pmid">15947099</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takizawa</surname><given-names>I</given-names></name><name><surname>Lawrence</surname><given-names>MG</given-names></name><name><surname>Balanathan</surname><given-names>P</given-names></name><name><surname>Robello</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>HB</given-names></name><name><surname>Garg</surname><given-names>E</given-names></name><etal/></person-group><article-title>Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity</article-title><source>Oncotarget</source><year>2014</year><volume>6</volume><fpage>604</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2820</pub-id><pub-id pub-id-type="pmid">25436982</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Urano</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Ouchi</surname><given-names>Y</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>289</volume><fpage>692</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.6038</pub-id><pub-id pub-id-type="pmid">11726203</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneja</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>MR</given-names></name><name><surname>Dalton</surname><given-names>JT</given-names></name><name><surname>Raghow</surname><given-names>S</given-names></name><name><surname>Barnette</surname><given-names>G</given-names></name><name><surname>Steiner</surname><given-names>M</given-names></name><etal/></person-group><article-title>Toremifene-a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy</article-title><source>Expert Opin Investig Drugs</source><year>2006</year><volume>15</volume><fpage>293</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1517/13543784.15.3.293</pub-id><pub-id pub-id-type="pmid">16503765</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stein</surname><given-names>B</given-names></name><name><surname>Sieber</surname><given-names>P</given-names></name><name><surname>Tutrone</surname><given-names>R</given-names></name><name><surname>Bailen</surname><given-names>J</given-names></name><name><surname>Goluboff</surname><given-names>E</given-names></name><etal/></person-group><article-title>Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB trial</article-title><source>J Urol</source><year>2006</year><volume>176</volume><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2006.04.011</pub-id><pub-id pub-id-type="pmid">16890670</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname><given-names>BL</given-names></name><name><surname>Hartman</surname><given-names>LC</given-names></name></person-group><article-title>Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>618</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1056/NEJMra022219</pub-id><pub-id pub-id-type="pmid">12584371</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shazer</surname><given-names>RL</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Galkin</surname><given-names>AV</given-names></name><name><surname>Cinman</surname><given-names>N</given-names></name><name><surname>Nguyen</surname><given-names>KN</given-names></name><name><surname>Natale</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Raloxifene, an oestrogen-receptor-&#x003b2; targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial</article-title><source>BJU Int</source><year>2006</year><volume>97</volume><fpage>691</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2006.05974.x</pub-id><pub-id pub-id-type="pmid">16536755</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soloway</surname><given-names>MS</given-names></name><name><surname>Hardeman</surname><given-names>SW</given-names></name><name><surname>Hickey</surname><given-names>D</given-names></name><name><surname>Raymond</surname><given-names>J</given-names></name><name><surname>Todd</surname><given-names>B</given-names></name><name><surname>Soloway</surname><given-names>S</given-names></name><etal/></person-group><article-title>Stratification of patients with metastatic prostate cancer based on disease on initial bone scan</article-title><source>Cancer</source><year>1988</year><volume>61</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19880101)61:1&#x0003c;195::AID-CNCR2820610133&#x0003e;3.0.CO;2-Y</pub-id><pub-id pub-id-type="pmid">3334948</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooperberg</surname><given-names>MR</given-names></name><name><surname>Hinotsu</surname><given-names>S</given-names></name><name><surname>Namiki</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Broering</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>4306</fpage><lpage>4313</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.5228</pub-id><pub-id pub-id-type="pmid">19667269</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottet</surname><given-names>N</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Bolla</surname><given-names>M</given-names></name><name><surname>Joniau</surname><given-names>S</given-names></name><name><surname>Mason</surname><given-names>M</given-names></name><name><surname>Matveev</surname><given-names>V</given-names></name><etal/></person-group><article-title>EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer</article-title><source>Eur Urol</source><year>2011</year><volume>59</volume><fpage>572</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2011.01.025</pub-id><pub-id pub-id-type="pmid">21315502</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinotsu</surname><given-names>A</given-names></name><name><surname>Niimi</surname><given-names>M</given-names></name><name><surname>Akaza</surname><given-names>H</given-names></name><etal/></person-group><article-title>Development of Japanese version of QOL questionnaire for bladder and prostate cancer patients using FACT-Bl and P: Pilot study</article-title><source>Gan To Kagaku Ryoho</source><year>1999</year><volume>26</volume><fpage>657</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">10234297</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Urano</surname><given-names>T</given-names></name><name><surname>Takayama</surname><given-names>K</given-names></name><name><surname>Sugihara</surname><given-names>T</given-names></name><name><surname>Obinata</surname><given-names>D</given-names></name><etal/></person-group><article-title>Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>4625</fpage><lpage>4635</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1105</pub-id><pub-id pub-id-type="pmid">24987058</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Higano</surname><given-names>C</given-names></name><name><surname>Schelhammer</surname><given-names>PF</given-names></name><name><surname>Faulkner</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><etal/></person-group><article-title>Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162)</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3984</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.06.4246</pub-id><pub-id pub-id-type="pmid">16921051</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawashima</surname><given-names>H</given-names></name><name><surname>Nakatani</surname><given-names>T</given-names></name></person-group><article-title>Involvement of estrogen receptors in prostatic tissues</article-title><source>Int J Urol</source><year>2012</year><volume>19</volume><fpage>512</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2042.2012.02987.x</pub-id><pub-id pub-id-type="pmid">22375605</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turo</surname><given-names>R</given-names></name><name><surname>Smolski</surname><given-names>M</given-names></name><name><surname>Esler</surname><given-names>R</given-names></name><name><surname>Kujawa</surname><given-names>ML</given-names></name><name><surname>Bromage</surname><given-names>SJ</given-names></name><name><surname>Oakley</surname><given-names>N</given-names></name><etal/></person-group><article-title>Diethylstilboestrol for the treatment of prostate cancer: past, present and future</article-title><source>Scand J Urol</source><year>2014</year><volume>48</volume><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3109/21681805.2013.861508</pub-id><pub-id pub-id-type="pmid">24256023</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonard</surname><given-names>DM</given-names></name><name><surname>Smith</surname><given-names>CL</given-names></name></person-group><article-title>Molecular perspectives on selective estrogen receptors (SERMs): progress in understanding their tissue-specific agonist and antagonist actions</article-title><source>Steroids</source><year>2002</year><volume>67</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S0039-128X(01)00133-7</pub-id><pub-id pub-id-type="pmid">11728517</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghow</surname><given-names>S</given-names></name><name><surname>Hooshdaran</surname><given-names>MZ</given-names></name><name><surname>Katiyar</surname><given-names>S</given-names></name><name><surname>Steiner</surname><given-names>MS</given-names></name></person-group><article-title>Toremifene prevents prostate cancer in transgenic adenocarcinoma of mouse prostate model</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>1370</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11888907</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MR</given-names></name><name><surname>Malkowicz</surname><given-names>SB</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Forrest</surname><given-names>J</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Sieber</surname><given-names>P</given-names></name><etal/></person-group><article-title>Toremifene increase bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of multicenter phase 3 clinical study</article-title><source>J Urol</source><year>2008</year><volume>179</volume><fpage>152</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2007.08.137</pub-id><pub-id pub-id-type="pmid">18001802</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MR</given-names></name><name><surname>Malkowicz</surname><given-names>SB</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Forrest</surname><given-names>J</given-names></name><name><surname>Sieber</surname><given-names>P</given-names></name><name><surname>Barnette</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Toremifene improves lipid profiles in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of multicenter phase 3 clinical study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1824</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.13.5517</pub-id><pub-id pub-id-type="pmid">18398147</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutertre</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>CL</given-names></name></person-group><article-title>Molecular mechanisms of selective estrogen receptors (SERM) action</article-title><source>J Pharmacol Exp Ther</source><year>2000</year><volume>295</volume><fpage>431</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11046073</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>MW</given-names></name><name><surname>Flowers</surname><given-names>DE</given-names></name><name><surname>Huster</surname><given-names>WJ</given-names></name><name><surname>Neild</surname><given-names>JA</given-names></name><name><surname>Harper</surname><given-names>KD</given-names></name><name><surname>Arnaud</surname><given-names>C</given-names></name></person-group><article-title>A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women</article-title><source>J Bone Miner Res</source><year>1996</year><volume>11</volume><fpage>835</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/jbmr.5650110615</pub-id><pub-id pub-id-type="pmid">8725181</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kangas</surname><given-names>L</given-names></name></person-group><article-title>Review of the pharmacological properties of toremifene</article-title><source>J Steroid Biochem</source><year>1990</year><volume>36</volume><fpage>191</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/0022-4731(90)90003-B</pub-id><pub-id pub-id-type="pmid">2142231</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megas</surname><given-names>G</given-names></name><name><surname>Chrisofos</surname><given-names>M</given-names></name><name><surname>Anastasiou</surname><given-names>I</given-names></name><name><surname>Tsitlidou</surname><given-names>A</given-names></name><name><surname>Choreftaki</surname><given-names>T</given-names></name><name><surname>Deliveliotis</surname><given-names>C</given-names></name></person-group><article-title>Estrogen receptor (&#x003b1; and &#x003b2;) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer</article-title><source>Asian J Androl</source><year>2015</year><volume>17</volume><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.4103/1008-682X.136445</pub-id><pub-id pub-id-type="pmid">25219910</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>Y</given-names></name><name><surname>Akaogi</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Osakabe</surname><given-names>A</given-names></name><name><surname>Yamaguchi</surname><given-names>C</given-names></name><name><surname>Sunahara</surname><given-names>N</given-names></name><etal/></person-group><article-title>Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ER&#x003b2; and KLF5</article-title><source>Sci Signal.</source><year>2011</year><volume>4</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1126/scisignal.2001551</pub-id><pub-id pub-id-type="pmid">21325206</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadaha</surname><given-names>MK</given-names></name><name><surname>Ashraf</surname><given-names>U</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Levine</surname><given-names>E</given-names></name><name><surname>Silliman</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer</article-title><source>Prostate</source><year>2008</year><volume>68</volume><fpage>1461</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/pros.20813</pub-id><pub-id pub-id-type="pmid">18618738</pub-id></element-citation></ref></ref-list></back></article>